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I In nt tr ro od du uc ct ti io on n
The Cold Spring Harbor Laboratory Biology of Genomes
meeting is one of the most eagerly awaited events in the
genomics calendar, and this year’s meeting [1] did not dis-
appoint: participants were treated to four days of cutting-
edge research on a diverse array of topics. This report
focuses on the major themes of the meeting relevant to the
field of medical genomics.
A An n   e ex xp pl lo os si io on n   o of f   s se eq qu ue en nc ce e   d da at ta a
The single dominant message emerging from this year’s
meeting was simple: advances in DNA sequencing technology
are now enabling the generation of biological data at a
frightening (and accelerating) pace. Increasing sequencing
capacity promises rapid advances in biological under-
standing, but it also brings tremendous challenges in terms of
storing, disseminating and analyzing vast quantities of data.
Both the power and the challenges of large-scale sequencing
data were evident in the first session of the meeting, which
focused on cancer genomics. Several speakers in this
session, including Mike Stratton (Wellcome Trust Sanger
Institute, Hinxton, UK), Elaine Mardis (Washington Univer-
sity, St Louis, USA) and Gad Getz (Broad Institute,
Cambridge, USA), discussed progress in the use of large-
scale sequencing to develop comprehensive catalogs of the
genetic changes underlying cancer progression.
The general strategy is to generate sequence data from both
tumor samples and normal tissue from the same patient;
genetic differences between the two samples represent
candidates for somatic changes occurring during cancer
progression. Stratton presented results from low-coverage
sequencing of 24 breast cancer genomes, illustrating the
power of this approach for the detection of structural variants
(SVs); Mardis and Getz both presented high-coverage
sequencing of smaller numbers of cancer samples for
combined analysis of SVs and smaller-scale genetic variation.
These approaches have successfully generated high-
resolution snapshots of genetic variation in tumors, but
many challenges remain. For instance, there are many
different sources of sequencing artifacts, and Getz
emphasized the need for very careful control of false positive
rates to ensure that the list of candidate somatic changes is
as reliable as possible. In addition, interpreting the func-
tional effects of variants that fall outside protein-coding
regions remains very difficult, and discriminating between
mutations underlying cancer progression (‘drivers’) and
changes resulting from a general decrease in genomic
stability (‘passengers’) requires variants in many cancers to
be assayed to look for those present multiple times. This task
will be eased by the generation of whole-genome sequence
data on hundreds of tumors and matched normal samples;
Mardis noted that Washington University plans to sequence
samples from 150 cancer patients over the next 12 months.
Although the number of cancer genome sequencing projects
currently underway is impressive, when it comes to sheer
scale it is hard to compete with the 1000 Genomes (1KG)
Project [2]. This massive international collaboration aims togenerate a near-comprehensive catalog of human genetic
variants with a frequency above 1% by performing whole-
genome sequencing on some 1,500 individuals from Europe,
Asia and Africa.
Early results from three pilot projects conducted by the 1KG
consortium were presented by Gonçalo Abecasis (University
of Michigan, Ann Arbor, USA). The pilot projects are am-
bitious undertakings in their own right: low-coverage
(approximately 4X) whole-genome sequencing of 180
individuals, very high-coverage (over 30X) of six individuals,
and targeted resequencing of 1,000 randomly selected genes
in several hundred individuals. These analyses have already
contributed substantially to the catalog of human genetic
variation, identifying 21.7 million single nucleotide poly-
morphisms (SNPs; 11.2 million novel), 400,000 short
insertion/deletion variants and over 4,000 larger SVs. These
numbers will only increase as the project enters its main
phase; the participants have committed to sequencing 1,200
low-coverage genomes by the end of 2009.
The immediate utility of 1KG data for researchers was neatly
illustrated by several other presentations at the meeting. Gil
McVean (University of Oxford, UK) demonstrated that 1KG
sequence data could be used to increase the power of
existing genome-wide association study data through the use
of genotype imputation, while Michael Snyder (Yale
University, New Haven, USA) and Tony Kwan (McGill Uni-
versity, Montreal, Canada) have already used early release
1KG data to look for genetic variants associated with
variation in transcription factor binding and gene expres-
sion, respectively.
The data being generated by new sequencing technology
extend well beyond human genomic DNA. To provide just
two examples from the meeting: Stephen Montgomery
(Wellcome Trust Sanger Institute, Hinxton, UK) presented
the use of RNA sequencing for identifying variants
associated with variation in gene expression and alternative
splicing, while Claire Fraser-Liggett (University of Maryland,
USA) described sequence-based exploration of microbial
communities living on and in the human body.
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The second major theme from the meeting was the need for
diverse approaches for generating biological meaning from
sequence data. This need grows ever more urgent as
mountains of data generated by new sequencing technology
begin to accumulate, and as we move into the era of personal
genome sequencing.
One important task is to determine precisely which regions
of the human genome are actually functional, allowing
variants found in those regions to be prioritized for follow-up.
Several approaches to functional annotation were presented
at the meeting. Michele Clamp (Broad Institute, Cambridge,
USA) and Adam Siepel (Cornell University, Ithaca, USA)
both presented on the use of comparative genomic data from
nearly 30 mammalian species to highlight regions of strong
evolutionary conservation. Rick Myers (HudsonAlpha
Institute,  Huntsville, USA) described the integrated and
collaborative approach taken by the ENCODE Project
Consortium, which ultimately aims to characterize all of the
functional elements in the human genome. The extension of
detailed functional annotation into non-coding regions is
particularly crucial; David Goode (Stanford University,
Stanford, USA) argued on the basis of evolutionary constraint
that over 90% of the functional variation in any individual
human genome lies outside protein-coding regions.
Another important goal is to characterize the genetic
architecture of human diseases and complex traits, moving
beyond the common SNPs that have formed the backbone of
recent genome-wide association studies. Peter Donnelly
(University of Oxford, UK) presented an analysis of large-
scale copy number variations (CNVs) in the large Wellcome
Trust Case Control Consortium set of common disease and
control cohorts, laying out the daunting technical challenges
of genotyping CNVs and the risk of false positive
associations resulting from artifacts. More positively, he also
suggested that (contrary to previous reports) most common
easily assayable CNVs are actually well captured by existing
SNP chips.
Rare and de novo genetic variation is another currently
poorly surveyed region of the human genetic landscape.
Jonathan Cohen (University of Texas Southwestern Medical
Center, Dallas, USA) described rare variants associated with
lipid levels and noted the benefits of surveying multiple
populations for rare variant discovery. Philip Awadalla
(University of Montreal, Canada) described a resequencing
study of 401 synaptic genes, revealing an excess of
deleterious  de novo mutations in these genes in schizo-
phrenia and autism patients. In addition to emphasizing the
power of large-scale resequencing of patients and controls to
identify rare disease-associated variants, Awadalla sounded
a cautionary note for researchers analyzing cell-line
samples: 13 of 28 putative de novo variants were determined
to be cell-line artifacts, highlighting the need for storing
original blood-derived DNA from patients for validation.
C Co on nc cl lu us si io on ns s
The presentations at the meeting illustrated the growing
power of new sequencing technologies to uncover disease-
related genetic variants, as well as highlighting several
important challenges: the management of very large
datasets, the careful analysis required to avoid systematic
artifacts, and the need for the integration of multiple data
sources to guide biological interpretation. In particular,
although considerable attention has been focused on the
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association, it is clear that the detection, validation and
clinical interpretation of both of these classes of variants
remain problematic. We clearly have much more work to do
before our ability to make biological sense of sequence data -
and design clinical interventions accordingly - advances to
match our ability to generate such data.
Finally, the breadth and quality of the research presented at
the Biology of Genomes meeting continues to impress, and it
is likely that the already fierce competition for the limited
places at the meeting will continue to intensify; those
interested in the 2010 meeting would be well advised to
register early! As per CSHL meeting policy all presenters
have granted permission for the description of their work in
this article.
A Ab bb br re ev vi ia at ti io on ns s
1KG, 1000 Genomes; CNV, copy number variation; SNP,
single nucleotide polymorphism; SV, structural variation.
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